Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Sponsor: Kite, A Gilead Company
Summary
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) who have not previously received Bruton's tyrosine kinase inhibitor (BTKi).
Official title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
95
Start Date
2021-04-23
Completion Date
2025-06-17
Last Updated
2026-08-18
Healthy Volunteers
No
Conditions
Interventions
Fludarabine
Administered as intravenous infusion
Cyclophosphamide
Administered as intravenous infusion
Brexucabtagene autoleucel
Administered as intravenous infusion
Locations (40)
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Stanford University
Palo Alto, California, United States
University California Los Angeles (UCLA)
Santa Monica, California, United States
Sarah Cannon- Denver
Denver, Colorado, United States
University of Miami
Miami, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
Advocate Aurora Health - Advocate Lutheran General Hospital
Park Ridge, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
University of Rochester
Rochester, New York, United States
Duke University
Durham, North Carolina, United States
Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Sarah Cannon - Tenessee
Nashville, Tennessee, United States
Vanderbilt University
Nashville, Tennessee, United States
Baylor Cancer Hospital
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Swedish Cancer Institute
Seattle, Washington, United States
CHU de Montpellier
Montpellier, France
Hospital Saint Louis
Paris, France
Hopital Haut-Leveque
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
CHU de Rennes
Rennes, France
Johannes Gutenberg University Hospital-University Mainz
Mainz, Germany
Munich University of Technology-Medical Faculty- Ethics Committee
München, Germany
Universitaetsklinikum Wuerzburg
Würzburg, Germany
Academisch Medisch Centrum
Amsterdam, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Erasmus MC
Rotterdam, Netherlands
Hospital Universitari Vall D'Hebron
Barcelona, Spain
Hospital Clinic Barcelona
Barcelona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Queen Elizabeth University Hospital
Glasgow, United Kingdom
Kings College Hospital
London, United Kingdom
Manchester Royal Infirmary
Manchester, United Kingdom